FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

被引：0

作者：

Lixia Gao

Xuli Wang

Yaoliang Tang

Shuang Huang

Chien-An Andy Hu

Yong Teng

机构：

[1] Augusta University,Department of Oral Biology, Dental College of Georgia

[2] University of Utah,Department of Radiology and Imaging Sciences, School of Medicine

[3] University of Utah,Experimental Therapeutics Program, Huntsman Cancer Institute

[4] Augusta University,Vascular Biology Center, Department of Medicine, Medical College of Georgia

[5] University of Florida College of Medicine,Department of Anatomy and Cell Biology

[6] University of New Mexico School of Medicine,Department of Biochemistry and Molecular Biology

[7] Augusta University,Department of Biochemistry and Molecular Biology, Medical College of Georgia

来源：

Journal of Experimental & Clinical Cancer Research | / 36卷

关键词：

FGF19; FGFR4; Hepatocellular carcinoma; Drug resistance; Sorafenib; Synergistic effect;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] PRECISION THERAPY IN HEPATOCELLULAR CARCINOMA: ASSOCIATION OF FGF3, FGF4, AND FGF19 AMPLIFICATION WITH RESPONSE TO SORAFENIB
Hassan, Hind
Ali, Mohamed Abdulwahab Mohamed
O'Brien, Daniel
Hassan, Fatma
Tadakamalla, Anirudh
Taha, Wesam
Wang, Chen
Kocher, Jean-Pierre
Borad, Mitesh
Lam-Himlin, Dora M.
Cleary, Sean
Torbenson, Michael
Roberts, Lewis R.
HEPATOLOGY, 2023, 78 : S1869 - S1870
[22] DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
Chen, Xin
Yang, Guohua
Guo, Xiaohong
Zhang, Jing
Sun, Wei
Liu, Dongbo
Wang, Hui
Liu, Shunfang
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
[23] Mechanisms of resistance toward FGFR4 inhibition in hepatocellular carcinoma
Zhang, N.
Shen, B.
Shi, J.
Zhu, Z.
Zhang, Y.
Ying, H.
Chen, Z.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S111 - S111
[24] EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma
Shen, Bin
Shi, Jue-Ping
Zhu, Zhi-Xuan
He, Zhi-Dong
Liu, Shen-Yan
Shi, Wan
Zhang, Yong-Xian
Ying, Hai-Yan
Wang, Jie
Xu, Rui-Feng
Fang, Fei
Chang, Harrison Xuesong
Chen, Zhui
Zhang, Nan-Nan
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1479 - 1492
[25] NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors
Weiss, Andreas
Porta, Diana Graus
Reimann, Flavia
Buhles, Alexandra
Stamm, Christelle
Fairhurst, Robin A.
Kinyamu-Akunda, Jacqueline
Sterker, Dario
Murakami, Masato
Wartmann, Markus
Wang, Youzhen
Engelman, Jeffrey A.
Hofmann, Francesco
Sellers, Wiliam R.
CANCER RESEARCH, 2017, 77
[26] miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
Lin Ji
Zhongjie Lin
Zhe Wan
Shunjie Xia
Shi Jiang
Dong Cen
Liuxin Cai
Junjie Xu
Xiujun Cai
Cell Death & Disease, 11
[27] miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
Ji Lin
Lin Zhongjie
Wan Zhe
Xia Shunjie
Jiang Shi
Cen Dong
Cai Liuxin
Xu Junjie
Cai Xiujun
CELL DEATH & DISEASE, 2020, 11 (04)
[28] FGF19-Based Mini Probe Targeting FGFR4 for Diagnosis and Surgical Navigation of Hepatocellular Carcinoma
Cai, Jiaxian
Lian, Chen
Lu, Zeyu
Shang, Qian
Wang, Li
Han, Zhihao
Gu, Yueqing
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 3764 - 3777
[29] FGF19和FGFR4在肿瘤中作用的研究进展
方科
苏子剑
庄建良
中国肿瘤外科杂志, 2013, 5 (01) : 64 - 67
[30] Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma
Hatlen, Megan A.
Schmidt-Kittler, Oleg
Sherwin, Cori-Ann
Rozsahegyi, Emily
Rubin, Nooreen
Sheets, Michael
Kim, Joseph L.
Miduturu, Chandra
Bifulco, Neil
Brooijmans, Natasja
Shi, Hongliang
Guzi, Timothy
Boral, Andy
Lengauer, Christoph
Dorsch, Marion
Kim, Richard D.
Kang, Yoon-Koo
Wolf, Beni B.
Hoeflich, Klaus P.
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)

← 1 2 3 4 5 →